133242-34-9Relevant academic research and scientific papers
Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101
Iguchi,Iwamura,Nishizaki,Hayashi,Senokuchi,Kobayashi,Sakaki,Hachiya,Ichioka,Kawamura
, p. 1462 - 1469 (2007/10/02)
A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.
Novel esters of phenylalkanoic acid
-
, (2008/06/13)
The esters of phenylalkanoic acid of the formula: STR1 wherein R 1 is 4-10 membered, saturated or unsaturated, mono- or bi-cyclic hetero ring containing as hetero atoms:(i) one or two nitrogen,(ii) two or three of nitrogen and sulfur in total, or(iii) one or two sulfur;R 2 is hydrogen; orR 1 and R 2, taken together with a nitrogen to which they are attached, form 4-7 membered, saturated or unsaturated, mono-cyclic hetero ring containing as hetero atoms:(i) one or two nitrogen, or(ii) two or three of nitrogen and oxygen in total,the aforementioned hetero rings, represented by R 1 or formed by R 1 and R 2, taken together with a nitrogen to which they are attached, may be substituted by one substituent selected from C1-4 alkyl and C2-5 acyl;R 3 each, independently, is hydrogen or C1-4 alkyl;R 4 is hydrogen, halogen, trihalomethyl, C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, cyano, nitro or nitroxy;R 5 each, independently, is hydrogen, C1-4 alkyl or phenyl; or the two R 5 ''s, taken together with a carbon to which they are attached, form cyclopentane or cyclohexane;and the pharmaceutically acceptable acid addition salts thereof, have β 1 -adrenergic receptor blocking activity, and therefore, are useful for the prevention of and/or in the treatment of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia, etc.
